874379-35-8Relevant articles and documents
RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
-
, (2020/07/06)
Provided herein are a RET inhibitor, a pharmaceutical composition thereof and uses thereof. In particular, provided is a compound having Formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. Provided is a pharmaceutical composition comprising the compound, and uses of the compound and pharmaceutical composition thereof for the preparation of a medicament, in particular for treatment and prevention of RET-related diseases and conditions, including cancer, irritable bowel syndrome, and/or pain associated with irritable bowel syndrome.
Synthetic approaches to polypyridyl bridging ligands with proximal multidentate binding sites
Zong, Ruifa,Wang, Dong,Hammitt, Richard,Thummel, Randolph P.
, p. 167 - 175 (2007/10/03)
A series of 12 bridging ligands was prepared. These ligands include a central linker appended to two 1,8-naphthyrid-2-yl or two 1,10-phenanthrolin-2- yl units. The linkers include pyridazin-3,6-diyl, 1,8-naphthyrid-2,7-diyl, 2,2′-bipyrid-6,6′-diyl, 1,10-phenanthrolin-2,9-diyl, 1,2-di(2′-pyrid-6′-yl)ethyne, and 3,6-di(2′-pyrid-6′-yl) pyridazine. The ligands were synthesized from the diacetyl derivative of the central linker by a Friedlaender condensation with either 2-aminonicotinaldehyde or 8-amino-7-quinolinecarbaldehyde. The precursor diacetyl derivatives were, in turn, prepared by pathways involving Stille and Sonogashira couplings. Examination of the electronic absorption spectra of the bridging ligands shows the strongest correlation to be between pairs of ligands having the same central linker. Complexation studies will follow.
